Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 9:44 PM ET

Company Overview of Weill Cornell Medical College, New York

Company Overview

Weill Cornell Medical College, New York is an educational institution.

525 East 68th Street

New York, NY 10065

United States





Key Executives for Weill Cornell Medical College, New York

Weill Cornell Medical College, New York does not have any Key Executives recorded.

Weill Cornell Medical College, New York Key Developments

Weill Cornell Medical College, New York Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 05:00 PM

Weill Cornell Medical College, New York Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 05:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Christopher Mason, Associate Professor.

Agilent Technologies Inc. Collaborates with Weill Cornell Medical College, in New York, to Advance Research in Amyotrophic Lateral Sclerosis

Agilent Technologies Inc. has announced that it is collaborating with Weill Cornell Medical College, in New York, to advance research in amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Agilent will provide the latest mass spectrometry technology to support in research, working toward an understanding of how the most common form of this disease develops in the body. The Agilent 6230B LC TOF and 6550A LC Q-TOF mass spectrometers will be housed in the laboratory of Dr. Steven Gross.

Weill Cornell Medical College and Cellectis Announces Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia

Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The alliance will foster the development of Cellectis lead product candidate in AML, called UCART123. The collaboration combines Weill Cornell's broad expertise and resources in translational stem cell science and developmental therapeutics with Cellectis work in development and manufacturing of gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor. The research will be led by co-principal investigators Dr. Gail J. Roboz, director of the leukemia program and an associate professor of medicine at Weill Cornell, and Dr. Monica Guzman, an assistant professor of pharmacology in medicine at Weill Cornell. Dr. Roboz is an internationally recognized leader in the field of acute leukemia and will design and implement clinical testing of UCART123 in patients with AML. Dr. Guzman is a renowned leukemia stem cell biologist who specializes in preclinical and early-stage testing to optimize the development of stem cell-targeted cancer drugs. The alliance will seek to accelerate the development of Cellectis UCART123 in AML. Cellectis proprietary allogeneic CAR T-cell platform utilizes T-cells (immune cells) from healthy donors. The T-cells are engineered with a Chimeric Antigen Receptor (CAR), which enables them to detect specific proteins (antigens) expressed on malignant tumors. Large numbers of allogeneic CAR-modified T-cells are grown in the laboratory and then infused into a patient. The enhanced cells are designed to recognize and attack stem cells harboring the CD123 antigen, which is present on AML blast and stem cells. To enhance safety and minimize toxicity for patients, the company's gene-editing process features customized control properties that seek to prevent the T cells from inappropriately attacking healthy tissues.

Similar Private Companies By Industry

Company Name Region
Lifesurance Corp United States
Walt Disney Records United States
Antenucci Electric, Inc. United States
Canyon Ranch Enterprises United States
B&G Industries, Ltd. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Weill Cornell Medical College, New York, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at